Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.

American journal of blood research Pub Date : 2021-04-15 eCollection Date: 2021-01-01

Aditya Kumar Gupta, Prasanth Srinivasan, Gargi Das, Jagdish Prasad Meena, Pranay Tanwar, Rachna Seth

{"title":"Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.","authors":"Aditya Kumar Gupta, Prasanth Srinivasan, Gargi Das, Jagdish Prasad Meena, Pranay Tanwar, Rachna Seth","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited.Methods: The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records.Results: A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child.Conclusion: Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient.","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"168-171"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165717/pdf/ajbr0011-0168.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of blood research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited.

Methods: The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records.

Results: A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child.

Conclusion: Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient.

本刊更多论文

自体造血干细胞移植后的Eltrombopag -年轻儿科患者的新适应症。

背景:造血干细胞移植(HSCT)后中性粒细胞和血小板的植入是获得最佳结果的必要条件。成人造血干细胞移植后使用依曲巴来促进血小板生成。它在儿童造血干细胞移植后患者中的应用受到限制。方法:回顾性分析1例自体造血干细胞移植后患者的临床和实验室资料。结果:1例5岁男童因难治性霍奇金淋巴瘤自体造血干细胞移植后原发性血小板减少。虽然注入的干细胞剂量是足够的，但孩子的血小板植入有延迟。在排除HSCT后血小板减少的原因后，开始为孩子使用电曲巴。使用电血栓包后，患儿恢复了正常的血栓生成。结论:本例患者治疗移植后原发性血小板减少症有效且安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of blood research MEDICINE, RESEARCH & EXPERIMENTAL-

自引率

0.00%

发文量